UK – Perspectum, an Oxford, UK-based precision health company which develops medical imaging tools, raised $19M in the second close of its Series C funding.
The round, which brought the total amount of the Series C to $55M and general to $140M, was led by Oppenheimer.The company intends to use the funds to accelerate its product pipeline for multiorgan conditions and oncology.Led by CEO Rajarshi Banerjee, Perspectum is a global medical technology company that delivers digital technologies that help clinicians provide care for patients with chronic metabolic diseases, multi-organ pathology, and cancer. Its software products enhance the capabilities of a standard magnetic resonance imaging (MRI) machine, enabling it to capture multiparametric mapping data which allows its AI-driven software to measure organ inflammation with greater precision, aiding diagnosis and the monitoring of patients with chronic diseases. Since the beginning of 2021, 77 million US adults covered by Medicare and commercial plans have had access to LiverMultiScan, the company’s flagship diagnostic tool to assess and monitor chronic liver disease. The coverage and established reimbursement codes have fueled LiverMultiScan’s adoption by several major US hospitals. Perspectum is working to expand its footprint across the US and to scale to meet the increasing demands for assessing organ health. The company has offices in the US, the UK, Portugal, and Singapore.15/03/2023
